Alentis is a private company founded in 2019, following the completion of a CHF12.5m Series A financing.

The financing was co-led by Swiss venture capital firms BioMed Partners and BB Pureos Bioventures, with additional investments from Bpifrance, Schroder Adveq and the German High-Tech Gründerfonds

Alentis is actively seeking further investment to support the acceleration of its lead programs for fibrosis and fibrosis-driven cancers into clinical development, and to expand the wider potential of targeting CLDN1 in other fibrotic diseases.

For further information about our next investment round, please contact